Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wednesday, dashing remaining hopes that the widely used medication could help such patients. The Danish drugmaker said last week that the trials, which were designed to show that its semaglutide pill Rybelsus could slow progression of the brain-wasting disease by at least 20%, did not meet their goals. The joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to make a difference in delaying cognitive decline. Trial patients on Rybelsus did show significant suppression of a key marker of inflammation, but "we did not hav

See Full Page